Table 2.

Recent published series on anti-PDL-2 inhibitors-related cardiotoxicity.

Study*	Old (sex)	Type of cancer	Anti-PD-L1 type	Symptoms/Cardiotoxicity		Outcome
(Mahmood et al., 2018 [43]	75,F	Metastatic endometrial cancer	Durvalumab 1500 mg + tremelimumab 75 mg	Difficulty ambulating, dyspnea / Myocarditis, HF,CHB	Started on IV Methylprednisolone 1 mg/kg to 20 mg/kg on day 2, mycophenolate mofetil 1000 mg oral twice daily	Symptoms improve
(Altan et al., 2019) [60]	72/M	Lung cancer	Anti-PD-L1	Dyspnea, hypotension hypoxia / Pericarditis	N/A	Death
Altan et al., 2019) [65]	57/F	Lung cancer	Anti-PD-L1	Dyspnea, orthopnea, bilateral lower edema / Cardiac tamponade	N/A	No additional toxicity after reintroduction
(Liu et al., 2019) [66]	61/F	Lung cancer	Atezolizumab and nivolumab	Dyspnea, fatigue / Myocarditis		Deterioration
(Berner et al., 2018 [67]	69/M	Renal cell carcinoma	Avelumab and Axitinib	Fatigue, constipation hypertension / Cardiac arrest	Reduction of axitinib, amlodipine	Death
(Li J et al., 2019) [68]		Non-small cell lung cancer	Atezolizumab	Left ventricular dyfunction		Death

^*Reported as case reports.